The long range goal of the NCDDG/AIDS is to develop drugs for the prevention and treatment of acquired immune deficiency syndrome (AIDS). Program 2 will define the low resolution structure of the envelope protein of the virus responsible for this disease.
The specific aims are threefold.
The first aim i s to identify any structural domains of the protein which can be prepared by partial proteolytic cleavage and which retain native folded structure.
The second aim i s to determine whether the protein's cysteines exist as disulfides or as free sulfhydryl groups. If disulfides occur, the specific pairs of cysteines comprising the disulfides will be determined. The third goal is to identify the buried or exposed nature of different regions of the sequence. This information will assist in identifying exposed portions of the sequence which may function as peptide vaccines or targets for monoclonal antibodies. It will help define regions which interact with T4 lymphocytes and could be targets for drugs interfering with infection of lymphocytes. Data also will define regions which interact with viral matrix proteins called gag proteins and thereby could be targeted for drugs interfering with virus maturation. Finally, experiments will investigate whether naturally occurring proteolytic cleavage of envelope protein activates it for interaction with T4 cells. If so, drug inhibition of such cleavage might interfere with T4 infection. Envelop proteins produced in monkey cells will be treated with proteases, reagents modifying sulfhydryl groups and disulfides, and reagents which discriminate between tyrosines which are exposed on the surface or buried in the membrane lipid bilayer. Reagents and the envelope protein itself may incorporate radioactive labels to facilitate analysis of small amounts of material. Radiolabelled peptides of modified proteins will be separated by high pressure liquid chromatography and analyzed by a gas phase microsequencer to determine the position of modifications in the protein's amino acid sequence.

Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
State University of New York at Buffalo
Department
Type
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Dundr, M; Meier, U T; Lewis, N et al. (1997) A class of nonribosomal nucleolar components is located in chromosome periphery and in nucleolus-derived foci during anaphase and telophase. Chromosoma 105:407-17
Dundr, M; Leno, G H; Lewis, N et al. (1996) Location of the HIV-1 Rev protein during mitosis: inactivation of the nuclear export signal alters the pathway for postmitotic reentry into nucleoli. J Cell Sci 109 ( Pt 9):2239-51
Srinivasakumar, N; Hammarskjold, M L; Rekosh, D (1995) Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation. J Virol 69:6106-14
Dundr, M; Leno, G H; Hammarskjold, M L et al. (1995) The roles of nucleolar structure and function in the subcellular location of the HIV-1 Rev protein. J Cell Sci 108 ( Pt 8):2811-23
Berkowitz, R D; Hammarskjold, M L; Helga-Maria, C et al. (1995) 5' regions of HIV-1 RNAs are not sufficient for encapsidation: implications for the HIV-1 packaging signal. Virology 212:718-23
Mak, J; Jiang, M; Wainberg, M A et al. (1994) Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles. J Virol 68:2065-72
Hammarskjold, M L; Li, H; Rekosh, D et al. (1994) Human immunodeficiency virus env expression becomes Rev-independent if the env region is not defined as an intron. J Virol 68:951-8
Bray, M; Prasad, S; Dubay, J W et al. (1994) A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A 91:1256-60
Smith, A J; Srinivasakumar, N; Hammarskjold, M L et al. (1993) Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J Virol 67:2266-75
Keefer, M C; Bonnez, W; Roberts Jr, N J et al. (1991) Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis 163:448-53

Showing the most recent 10 out of 17 publications